Tag: healthcare

  • AI Enters Healthcare, This Time, as a Provider

    AI Enters Healthcare, This Time, as a Provider

    Utah is the first state to automize prescription refills through an artificial intelligence (AI)-driven platform: Doctronic. No active doctor reviewing in real time. No healthcare provider oversight. Just AI. The AI-driven platform originally went live in late 2023, but it was not until December 2025, that the state of Utah partnered with the platform to provide care to the residents of Utah.

    How Does Doctronic actually work?

    The patient completes a questionnaire regarding their symptoms and medication history; subsequently, the interface determines whether a prescription renewal is appropriate. The initial prescription must be written by a doctor, and the program is limited to 190 maintenance drugs that it can refill. Painkillers, injectables, controlled substances and substances for attention disorders are excluded. 

    What Problems Does it Aim to Solve?

    Three in four Americans navigate life trying to manage their chronic conditions.[1] Yet people can wait up to an entire month for a primary care visit in several states. This lapse in care results in delays in therapy. Indeed, it is common for a provider to see the patient for a follow up appointment when starting a new therapy, or before approving refills for a maintenance medication. Those of us working behind the counter see first-hand, the prevalence and complexity of this issue. Medication adherence is far more than a term providers lecture patients about. Medication non-adherence is the single, most preventable healthcare crisis that burdens Americans, and it is responsible for approximately 125,000 deaths and accounts for 10% of hospitalizations annually.[2]


    A common reason for non-adhearance is patients simply not understanding why they are taking the medication and its significance. This is where pharmacists can fill in the gaps and provide adequate counselling at the pharmacy counter. However, automating the prescription renewal process and removing a health care provider completely, does not foster an environment for thorough, personalized counseling. This could potentially lead to unfavorable outcomes when managing chronic conditions. How well can AI communicate the importance of medication adherence when the encounter is not even face-to-face?

    Doctronic also boasts an anonymity feature, and claims that no data is stored in their records. This could present obvious challenges, as there would be no opportunity to follow up between visits, and no access to medication history beyond what the patient provides, which often is inaccurate or incomplete. 


    Can a patient-AI relationship rival a patient-provider relationship?

    There have been legitimate concerns raised by several organizations as to the clinical soundness of this program. The Utah Academy of Family Physicians stated “[w]ithout the involvement of a trained healthcare provider, we risk the possibility of negative drug interactions…lack of clarity around how and when a patient will be referred to their physician, and the risk of misuse or abuse.” 

    The intake survey places a considerable amount of responsibility on the patient to be able to self-identify their symptoms, and to recount which medications they are currently taking as well as the appropriate dose. From my experience, the amount of patients who could independently do so, is few and far between. 

    More importantly, if Doctronic can supply up to 90-day supplies for refills, is it possible for a patient to go extended periods of time without visiting their primary care provider? Does this inclusion of AI come with the tradeoff of valuable patient-provider relationships? Is it a possible answer to the barriers people face to visit providers, or does it reinforce the growing mistrust of healthcare providers? 

    Final Thoughts: Advancing With Caution

    These questions, and several more, should be carefully considered before other states join Utah and fully integrate AI into their healthcare practices as a provider. We will continue to monitor developments and update the community accordingly. 

    [1] https://www.cdc.gov/chronic-disease/about/index.html

    [2] https://psnet.ahrq.gov/issue/hospital-admissions-associated-medication-non-adherence-systematic-review-prospective

    Leave a comment

  • “New year, New Me!” – Wegovy 

    “New year, New Me!” – Wegovy 

    On December 22, 2025, Novo Nordisk shocked the world with breaking news: Wegovy (semaglutide) was FDA-approved in an oral formulation at a dosage of 25mg for weight loss management. Indeed, semaglutide has long existed in an oral formulation as Rybelsus (an FDA approved medication for Type 2 Diabetes and Cardiovascular Risk Reduction dose in 7mg or 14mg). The important distinction is that the approval for the higher dosage, oral formulation is for weight management and to reduce the risk of cardiovascular events in obese individuals with heart disease.


    Who isn’t it for?

    As with all medications, there are some exemptions to therapy that include: individuals with Multiple Endocrine Neoplasia Type 2 (MEN2), or a personal or family history of Medullary Thyroid Cancer (MTC) or any allergies to the ingredients of Wegovy. Importantly, oral Wegovy should not be used concomitantly with any other GLP-1 agonists.


    OASIS Trials

    The OASIS trial was a 72 week trial used to determine the efficacy of oral Semaglutide 25mg for weight management. Week 1 was used to screen the participants, 64 weeks consisted of treatment, and the remaining 7 weeks were used for observation and follow up. Participants were randomly assigned either oral semaglutide or a placebo at a 2:1 ratio. The medications were dosed once a day in addition to lifestyle modifications.[1] The 64-week treatment for the Semaglutide group was conducted in a titrated fashion: 3mg once a day for 4 weeks; 7mg daily for 3 weeks; 14 mg for the next 4 weeks; then the target dose of 25mg once a day for the remaining 51 weeks of treatment.[2] The placebo group also received matching tablets for the same duration.  

    The estimated average change in body weight for the semaglutide group was 13.6%, and just 2.2% in the placebo group.[3] The change of Impact of Weight on Quality of life (IWQOL) is a self-reported questionnaire used to assess the impact of one’s weight on their functionality and quality of life. The IWQOL Physical function score was significantly higher in the semaglutide group (55.3.% versus the placebo group 34.8%). These findings are associated with a clinically significant improvement in quality of life and physical function.


    How Will This Affect Consumers?

    Novo Nordisk plans on rolling out the oral pill in January 5, 2026. That’s right, within days! This new formulation of such a highly sought out drug will provide consumers with a more convenient option to reach their weight loss goals and may potentially alleviate some demand for the injectable version. With commercial insurance plans, the projected cost would be $25 per one (1) month supply.[4] The Wegovy website offers self-pay plans for the initial, 1.5mg and 4mg dosages starting at $149 per month until April 15, 2026, then increasing to $199 per month. The self-pay offer for a 1-month supply of 9mg and 25mg (target/maintenance dose) would cost $299.


    [1] https://www.nejm.org/doi/full/10.1056/NEJMoa2500969

    [2] https://clinicaltrials.gov/study/NCT05564117

    [3] https://www.nejm.org/doi/full/10.1056/NEJMoa2500969

    [4] https://www.wegovy.com/about-wegovy/the-wegovy-pill.html


    Leave a comment

  • Hypertension Guidelines Updated–Key Takeaways!

    Hypertension Guidelines Updated–Key Takeaways!

    The American Heart Association (AHA) has spent the last eight years revamping the 2017 Hypertension Guidelines, and it shows. There have been a notable number of new recommendations and improvements with an emphasis on prevention and lifestyle modifications. The AHA has also shifted to a more collaborative treatment approach, including nuanced guidance to navigate this multifaceted disease state that burdens nearly half of adult Americans.[1]


    A New Method to Predicting the Probability of a Cardiovascular Event 

    Predicting risk of Cardiovascular (CVD) Events (PREVENT) replaces the Pooled Cohort Equations, a tool formerly used to calculate the 10-year risk of having a CVD event. PREVENT is the first of its kind that utilizes kidney, metabolic and socioeconomic factors to determine a more inclusive score. PREVENT predicts the 10- and 30-year risk for CVD events, including heart failure and Atherosclerotic CVD.[2]  Studies have shown underestimation among certain demographics, which have led to missed opportunities to intervene and begin treatment. Although in need of more fine tuning, by shifting to a more inclusive approach, PREVENT can provide a more complete baseline and improve patient outcomes. 


    Categorization of Hypertension Stages

    Historically, Prehypertension was defined as a systolic reading between 120-129 mm Hg and a diastolic reading of less than 80 mm Hg.[3] The new guidelines reclassified this simply as Hypertension or high blood pressure (BP), removing pre-hypertension all together, and prompting drug therapy initiation if the 10-year cardiovascular risk (defined by PREVENT score) is greater than, or equal to 7.5%. Hypertensive urgency is now a dated term, and is simply “hypertensive emergency”, a reading greater than180/120 mm Hg. 


    What About the Drug Therapy options?

    Same drug classes—different execution. In 2025, the AHA shifted from race-based therapy recommendations to an individualized approach. Previously, for African Americans, initial treatment options were either thiazide diuretics, or calcium channel blockers not an angiotension Enzyme Inhibitors or angiotension Receptor Blockers. Comparatively, in other demographics, all four drug classes were considered. Despite the AHA’s previous recommendations, it did not yield favorable outcomes; for example, from 2017-2020, the control rate of high blood pressure in African Americans was 18% worse than their counterparts.[4] The riddance of race-based blood pressure recommendations will hopefully encourage practitioners to create more individualized treatment plans.


    How Have the Therapy Recommendations Evolved?

    The new guidelines have introduced initiating two drugs when the patient has systolic 2 consecutive systolic readings of 130mm Hg instead of 140mm Hg (per 2017 guidelines). Fifty-percent of patients are non-adherent to their blood pressure medications one year after therapy initiation, so introducing two drugs may exacerbate this problem. What’s more, from a provider perspective, it would be difficult to pinpoint which side effect profile corresponds to which medication, thus further complicating dosage titrations. A solution to reducing pill burden would be combination products, which the guidelines encourage. However, due to the ever-changing healthcare landscape of prior authorizations and insurance formulary changes, combination medications may not be accessible for many.

    The Correlation Between High BP and Dementia: How in the World is Dementia Related to BP?

    Midlife high blood pressure is the leading risk factor for white matter abnormalities in the brain, which are markers related to cognitive decline and dementia. In the previous 2017 guidelines, there were hypotheses that controlling systolic BP may reduce the occurrence of certain types of dementia. Since then, those theories have been confirmed with various studies, and current guidance is that reaching a target goal of 130mm Hg/80mm Hg can prevent cognitive impairment. 

    More Stringent Blood Pressure Goals in Pregnancy

    Due to growing evidence that elevated BP can complicate pregnancy pre- and post-delivery, the new guidelines lowered the BP goal to 130mm Hg over 80mm Hg. The guidelines further recommend individuals that already have high blood pressure and are planning to become pregnant should be counseled on the use of aspirin to prevent preeclampsia. 

    [1] https://www.cdc.gov/high-blood-pressure/data-research/facts-stats/index.html

    [2] https://professional.heart.org/en/guidelines-and-statements/prevent-calculator

    [3] https://www.ahajournals.org/doi/10.1161/cir.0000000000000678

    [4] https://minorityhealth.hhs.gov/heart-disease-and-blackafrican-americans


    2 responses to “Hypertension Guidelines Updated–Key Takeaways!”

    1. Walt Avatar
      Walt

      very important article! Thanks for the info!

      Liked by 1 person

      1. Delphine Adams Avatar
        Delphine Adams

        Thank you for reading!

        Like

    Leave a comment